AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Behcet’s Disease Therapeutics Market - Advent of Novel Therapeutics to Boost Growth through 2019-2023 | Technavio

November 4, 2019
Behcet's Disease Therapeutics Market - Advent of Novel Therapeutics to Boost Growth through 2019-2023 | Technavio
Behcet's Disease Therapeutics Market - Advent of Novel Therapeutics to Boost Growth through 2019-2023 | Technavio

LONDON--(BUSINESS WIRE)--Nov 4, 2019--

According to a recent Technavio report, the Behcet’s disease therapeutics market is expected to grow by USD 224.55 million during 2019-2023. Growth in the Behcet’s disease therapeutics market can be attributed to many segments, one of which is the product segment comprising of small molecules and biologics. Industry participants are focusing on analyzing maximum growth opportunities in the market by considering their prospects in the fast-growing product segment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005698/en/

Technavio has announced its latest market research report titled global Behcet’s disease therapeutics market 2019-2023. (Graphic: Business Wire)

What are the Latest Trends?

There is a huge unmet need for the treatment of Behcet’s disease associated with genetic mutations and autoimmune disorders. Major Behcet’s disease therapeutics market trends, such as the advent of novel therapies will drive the market growth. This is encouraging many academic institutions and pharmaceutical companies to invest substantially in the R&D of novel therapies. Regenerative medicines such as gene therapy and hemopoietic cell transplantations are a few of the most advanced and heavily researched treatment methods. Most of the therapies are either in the discovery stage or pre-clinical stage. As per Technavio, the Behcet’s disease therapeutics market is forecast to grow at a CAGR of over 6% by 2023.

Get A Free Sample Analysis from theBehcet’s Disease Therapeutics Market Analysis

Companies are currently conducting research on novel gene therapies, among which, some are in the discovery stage and some in pre-clinical stage. These companies are attracted to start the research on gene therapy for Behcet’s disease due to recent advances in the research methods of these novel therapies.

Register for a free trial today and gain instant access to 10,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Developments in the field of Behcet’s Disease Therapeutics

Several vendors in the market are focusing on developing new products. For instance, Mylan NV has offered HULIO. It is a biosimilar of HUMIRA and used for the treatment of various autoimmune diseases such as Behcet’s disease.

Eisai Co. Ltd. is one of the several vendors operating in the Behcet’s disease therapeutics space. The company offers HUMIRA, which is extensively used by patients suffering from autoimmune diseases such as Behcet’s disease. It helps in alleviating pain and inflammation in these patients.

For Further Market Information

More insights like this on the U.S. and global markets can be found in a series of reports published by Technavio entitled the Osteonecrosis Therapeutics Market Analysis, Size, Trends | Global | 2019-2023 & Splenomegaly Therapeutics Market Analysis, Size, Trends | Global | 2019-2023.

Email us at media@technavio.com or register online for a brochure and synopsis

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical and more Healthcare industries.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005698/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website: https://www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 11/04/2019 05:30 PM/DISC: 11/04/2019 05:31 PM

http://www.businesswire.com/news/home/20191104005698/en